Výsledky vyhledávání - "E. F. Morand"

Akademický článek

Lack of involvement of lipocortin 1 in dexamethasone suppression of IL-1 release

Autor: E. F. Morand, D. Rickard, N. J. Goulding

Publikováno v: Mediators of Inflammation, Vol 2, Iss 1, Pp 49-52 (1993)

The annexin lipocortin 1 is reported to mediate some anti-inflammatory effects of glucocorticoids, but the mechanisms of this mediation are incompletely understood. The involvement of lipocortin 1 in glucocorticoid inhibition of monocyte interleukin

Externí odkaz: https://doaj.org/article/5ba593a15b9b49dcba8e822e9305f379

Zobrazit plný text záznamu

AB0425 WHAT DOES IT MEAN TO BE A DUAL BICLA AND SRI(4) RESPONDER? A POOLED ANALYSIS OF TWO PHASE 3 TRIALS IN PATIENTS WITH SLE

Autor: I. N. Bruce, K. Psachoulia, E. Maho, D. Isenberg, R. van Vollenhoven, R. Furie, E. F. Morand, C. Lindholm, M. Hultquist, R. Tummala

Publikováno v: Annals of the Rheumatic Diseases. 81:1340-1341

BackgroundThe BILAG–based Composite Lupus Assessment (BICLA) and SLE Responder Index ≥4 (SRI[4], based on SLEDAI-2K) are validated composite global measures of clinically meaningful improvement in SLE disease activity. BICLA and SRI(4) responses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0c9688a959321f5a2287cbfde5def8d
https://doi.org/10.1136/annrheumdis-2022-eular.900

Zobrazit plný text záznamu

POS0709 SUSTAINED BICLA AND BILAG ORGAN DOMAIN RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING ANIFROLUMAB IN TWO PHASE 3 TRIALS

Autor: R. Van Vollenhoven, R. Furie, E. F. Morand, R. Tummala, E. Maho, C. Lindholm

Publikováno v: Annals of the Rheumatic Diseases. 81:635-636

BackgroundIncomplete SLE disease control is associated with progressive organ damage, poor quality of life, and increased mortality.1–3 Sustained reduction in overall disease activity is therefore an important treatment goal.ObjectivesTo investigat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::423a9de6524163f4890b3886a0f718a4
https://doi.org/10.1136/annrheumdis-2022-eular.897

Zobrazit plný text záznamu

POS0190 EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES

Autor: E. F. Morand, Y. Tanaka, R. Furie, E. Vital, R. van Vollenhoven, K. Kalunian, M. Mosca, T. Dörner, D. J. Wallace, M. Silk, C. Dickson, I. De La Torre, G. Meszaros, B. Jia, B. Crowe, M. A. Petri

Publikováno v: Annals of the Rheumatic Diseases. 81:327-328

BackgroundIn a 24-week, phase 2 clinical study (NCT02708095) in patients with systemic lupus erythematosus (SLE), baricitinib (BARI), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75730e0eac0964885b9aa1eff66b7a7e
https://doi.org/10.1136/annrheumdis-2022-eular.1968

Zobrazit plný text záznamu

AB0444 ENPATORAN: PRECLINICAL EVIDENCE SUPPORTING GLUCOCORTICOID DOSE REDUCTION AND PHASE II STUDY DESIGN IN PATIENTS WITH SLE AND/OR CLE (WILLOW)

Autor: E. F. Morand, A. Bender, A. Deshpande, B. Vaidyanathan, C. Vazquez Mateo, M. Przetak, F. Moreau, M. Khursheed, S. Roy, D. Pearson

Publikováno v: Annals of the Rheumatic Diseases. 81:1350.2-1351

BackgroundEnpatoran is a potent selective dual inhibitor of toll-like receptor (TLR) 7 and TLR8, aberrant activation of which may be involved in systemic lupus erythematosus (SLE) pathogenesis and glucocorticoid resistance.1,2,3 Enpatoran suppressed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0778ed5d03912d397597652b16bbdffd
https://doi.org/10.1136/annrheumdis-2022-eular.4386

Zobrazit plný text záznamu

POS0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS

Autor: T. Dörner, Y. Tanaka, M. Mosca, I. N. Bruce, M. Cardiel, E. F. Morand, M. A. Petri, M. Silk, C. Dickson, G. Meszaros, M. Issa, L. Zhang, D. J. Wallace

Publikováno v: Annals of the Rheumatic Diseases. 81:639.1-639

BackgroundBaricitinib (BARI), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic dermatitis, has been evaluated in clinical studies in patients with systemic lupus erythematosus (SLE).Obj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a67cabee3179d1705faace4a056019e9
https://doi.org/10.1136/annrheumdis-2022-eular.2375

Zobrazit plný text záznamu

POS0733 DISCORDANCE BETWEEN PATIENT GLOBAL ASSESSMENT AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN THE MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)

Autor: L. Arnaud, R. Furie, E. F. Morand, C. Peschken, M. Aringer, E. Rapsomaniki, J. Hedberg, J. Knagenhjelm, C. Seo, T. Grünfeld Eén, B. Desta, A. Sorrentino, R. Tummala, H. Stirnadel-Farrant

Publikováno v: Annals of the Rheumatic Diseases. 81:649.2-650

BackgroundEmphasis in clinical research and care has been placed on the need to include evaluations that reflect the perspectives of both patients and physicians.ObjectivesThe goal of this study was to analyze patient and physician assessments and to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c20f0192557447bfa5ba08db8ec6fd2
https://doi.org/10.1136/annrheumdis-2022-eular.1373

Zobrazit plný text záznamu

Supplemental material for Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus

Autor: F B Vincent, R Kandane-Rathnayake, A Y Hoi, L Slavin, J D Godsell, A R Kitching, J Harris, C L Nelson, A J Jenkins, A Chrysostomou, M L Hibbs, P G Kerr, M Rischmueller, F Mackay, E F Morand

Supplemental material for Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus by F B Vincent, R Kandane-Rathnayake, A Y Hoi, L Slavin, J D Godsell, A R Kitching, J Harris, C L Nelson, A J Jenki

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7996dd55b84b4b272295d17f1285b22d

Zobrazit plný text záznamu

Glucocorticoid-induced leucine zipper governs the therapeutic potential of mesenchymal stem cells by inducing a switch from pathogenic to regulatory Th17 cells in a mouse model of collagen-induced arthritis

Autor: P, Luz-Crawford, G, Tejedor, A L, Mausset-Bonnefont, E, Beaulieu, E F, Morand, C, Jorgensen, D, Noël, F, Djouad

Publikováno v: Arthritisrheumatology (Hoboken, N.J.). 67(6)

Mesenchymal stem cells (MSCs) are potent immunosuppressive cells that have shown promise in the treatment of rheumatoid arthritis (RA). Deciphering the intrinsic characteristics of MSCs that correlate with their biologic activity will facilitate thei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f4f552b0cc16a065c74c0b1cf905e6ae
https://pubmed.ncbi.nlm.nih.gov/25708718

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání